Market Snapshot
S&P Futures
3,914.75
Dow Futures
31,478
Nasdaq Futures
12,132.75
Akero Therapeutics, Inc. (AKRO) stock declined over -1.92% intraday to trade at $10.72 a share on NASDAQ. The stock opened with a loss of -6.94% at $11.06 and touched an intraday high of $11.325, falling -1.92% against the last close of $10.93. The stock went to a low of $10.66 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-06-23 | $11.06 | $11.325 | $10.66 | $10.72 | 492,600 |
2022-06-22 | $11.52 | $11.98 | $10.85 | $10.93 | 594,800 |
2022-06-21 | $12.14 | $12.45 | $11.66 | $11.76 | 659,900 |
2022-06-17 | $10.19 | $12.98 | $10.19 | $12.16 | 2,497,900 |
2022-06-16 | $9.41 | $10.81 | $9.1 | $10.37 | 1,553,300 |
2022-06-15 | $8.09 | $8.52 | $7.93 | $8.5 | 380,000 |
2022-06-14 | $8.08 | $8.1 | $7.77 | $8.05 | 207,700 |
2022-06-13 | $8.25 | $8.34 | $7.52 | $8.06 | 451,100 |
2022-06-10 | $8.48 | $8.6 | $8.305 | $8.54 | 351,300 |
2022-06-09 | $9.15 | $9.3 | $8.55 | $8.55 | 245,100 |
Employees-
Beta-
Sales or Revenue0
5Y Sales Change-
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryBiotechnology
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Akero Therapeutics, Inc. (NASDAQ: AKRO) stock price is $10.72 as of the last check on Thursday, June 23. During the trading session, AKRO stock reached the peak price of $11.325 while $10.66 was the lowest point it dropped to.
The NASDAQ listed AKRO is part of Biotechnology industry that operates in the broader Health Care sector. Akero Therapeutics, Inc. , a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health.
Dr. Andrew Cheng M.D., Ph.D.
Pres, CEO & Director
Dr. Jonathan M. Young
Co-Founder, Exec. VP, COO & Sec.
Dr. Timothy Rolph
Co-Founder & Chief Scientific Officer
Mr. William R. White J.D.
Exec. VP, CFO, Treasurer & Head of Corp. Devel.
AKRO stock traded closed the last session at $10.72, which is $-0.21 or -1.92% lower than its previous close of $10.93. AKRO's current trading price is 42.55% lower than its 52-week high of $28.94 where as its distance from 52-week low of 7.52% is -62.96%.
Number of AKRO employees currently stands at -. AKRO operates from 601 Gateway Boulevard, Suite 350, South San Francisco, CA 94080, United States.
Official Webiste of $AKRO is: https://www.akerotx.com
AKRO could be contacted at AKRO operates from 601 Gateway Boulevard, Suite 350, South San Francisco, CA 94080, United States, or at phone #650 487 6488 and can also be accessed through its website.
AKRO stock volume for the day was 492,572 shares while in the previous session number of AKRO shares traded was 492,600 . The average number of AKRO shares traded daily for last 3 months was 335.91 Thousands.
The percentage change in AKRO stock occurred in the recent session was -1.92% while the dollar amount for the price change in AKRO stock was $-0.21.
In the recent session, the day high for AKRO stock was $11.325 while the low for AKRO stock touched on the day was $10.66.
The market value of AKRO currently stands at 320.21 Million with its latest stock price at $10.72 and 35.01 Million of its shares outstanding.